nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—SLC6A4—NRF2 pathway—DNAJB1—liver cancer	0.00185	0.0239	CbGpPWpGaD
Methylphenidate—Diplopia—Epirubicin—liver cancer	0.00182	0.00197	CcSEcCtD
Methylphenidate—Hot flush—Doxorubicin—liver cancer	0.0018	0.00195	CcSEcCtD
Methylphenidate—Increased appetite—Doxorubicin—liver cancer	0.00179	0.00194	CcSEcCtD
Methylphenidate—Migraine—Epirubicin—liver cancer	0.00179	0.00194	CcSEcCtD
Methylphenidate—Affect lability—Epirubicin—liver cancer	0.00179	0.00194	CcSEcCtD
Methylphenidate—Menopausal symptoms—Doxorubicin—liver cancer	0.00179	0.00194	CcSEcCtD
Methylphenidate—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00179	0.00194	CcSEcCtD
Methylphenidate—Hypersensitivity—Sorafenib—liver cancer	0.00178	0.00193	CcSEcCtD
Methylphenidate—Asthenia—Sorafenib—liver cancer	0.00174	0.00188	CcSEcCtD
Methylphenidate—Cardiac arrest—Epirubicin—liver cancer	0.00173	0.00188	CcSEcCtD
Methylphenidate—Hypoglycaemia—Doxorubicin—liver cancer	0.00173	0.00187	CcSEcCtD
Methylphenidate—Mood swings—Epirubicin—liver cancer	0.00173	0.00187	CcSEcCtD
Methylphenidate—Cerebrovascular accident—Doxorubicin—liver cancer	0.00172	0.00186	CcSEcCtD
Methylphenidate—Lethargy—Doxorubicin—liver cancer	0.00172	0.00186	CcSEcCtD
Methylphenidate—Pruritus—Sorafenib—liver cancer	0.00171	0.00186	CcSEcCtD
Methylphenidate—Dehydration—Epirubicin—liver cancer	0.00169	0.00184	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—SIX3—liver cancer	0.00169	0.0217	CbGpPWpGaD
Methylphenidate—Pain in extremity—Doxorubicin—liver cancer	0.00169	0.00183	CcSEcCtD
Methylphenidate—Diplopia—Doxorubicin—liver cancer	0.00169	0.00183	CcSEcCtD
Methylphenidate—Liver function test abnormal—Epirubicin—liver cancer	0.00168	0.00182	CcSEcCtD
Methylphenidate—Abdominal pain upper—Epirubicin—liver cancer	0.00166	0.0018	CcSEcCtD
Methylphenidate—CYP2D6—CYP2E1 reactions—CYP2E1—liver cancer	0.00166	0.0215	CbGpPWpGaD
Methylphenidate—Migraine—Doxorubicin—liver cancer	0.00166	0.0018	CcSEcCtD
Methylphenidate—Affect lability—Doxorubicin—liver cancer	0.00166	0.0018	CcSEcCtD
Methylphenidate—Diarrhoea—Sorafenib—liver cancer	0.00166	0.0018	CcSEcCtD
Methylphenidate—Breast disorder—Epirubicin—liver cancer	0.00165	0.00178	CcSEcCtD
Methylphenidate—Nasopharyngitis—Epirubicin—liver cancer	0.00163	0.00177	CcSEcCtD
Methylphenidate—Gastritis—Epirubicin—liver cancer	0.00161	0.00175	CcSEcCtD
Methylphenidate—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00161	0.00174	CcSEcCtD
Methylphenidate—Cardiac arrest—Doxorubicin—liver cancer	0.0016	0.00174	CcSEcCtD
Methylphenidate—Dizziness—Sorafenib—liver cancer	0.0016	0.00174	CcSEcCtD
Methylphenidate—Mood swings—Doxorubicin—liver cancer	0.0016	0.00173	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—DNAJB1—liver cancer	0.00159	0.0205	CbGpPWpGaD
Methylphenidate—Influenza—Epirubicin—liver cancer	0.00157	0.00171	CcSEcCtD
Methylphenidate—Asthma—Epirubicin—liver cancer	0.00157	0.00171	CcSEcCtD
Methylphenidate—Dehydration—Doxorubicin—liver cancer	0.00157	0.0017	CcSEcCtD
Methylphenidate—Liver function test abnormal—Doxorubicin—liver cancer	0.00156	0.00169	CcSEcCtD
Methylphenidate—Pancreatitis—Epirubicin—liver cancer	0.00154	0.00167	CcSEcCtD
Methylphenidate—Vomiting—Sorafenib—liver cancer	0.00154	0.00167	CcSEcCtD
Methylphenidate—Abdominal pain upper—Doxorubicin—liver cancer	0.00154	0.00167	CcSEcCtD
Methylphenidate—Angina pectoris—Epirubicin—liver cancer	0.00153	0.00166	CcSEcCtD
Methylphenidate—Rash—Sorafenib—liver cancer	0.00153	0.00166	CcSEcCtD
Methylphenidate—Dermatitis—Sorafenib—liver cancer	0.00153	0.00165	CcSEcCtD
Methylphenidate—Breast disorder—Doxorubicin—liver cancer	0.00152	0.00165	CcSEcCtD
Methylphenidate—Headache—Sorafenib—liver cancer	0.00152	0.00165	CcSEcCtD
Methylphenidate—Bronchitis—Epirubicin—liver cancer	0.00151	0.00164	CcSEcCtD
Methylphenidate—Nasopharyngitis—Doxorubicin—liver cancer	0.00151	0.00163	CcSEcCtD
Methylphenidate—Pancytopenia—Epirubicin—liver cancer	0.0015	0.00162	CcSEcCtD
Methylphenidate—Gastritis—Doxorubicin—liver cancer	0.00149	0.00162	CcSEcCtD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A2—liver cancer	0.00149	0.0192	CbGpPWpGaD
Methylphenidate—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00149	0.00161	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Epirubicin—liver cancer	0.00146	0.00159	CcSEcCtD
Methylphenidate—Influenza—Doxorubicin—liver cancer	0.00146	0.00158	CcSEcCtD
Methylphenidate—Asthma—Doxorubicin—liver cancer	0.00146	0.00158	CcSEcCtD
Methylphenidate—Nausea—Sorafenib—liver cancer	0.00144	0.00156	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Epirubicin—liver cancer	0.00144	0.00156	CcSEcCtD
Methylphenidate—Weight increased—Epirubicin—liver cancer	0.00143	0.00155	CcSEcCtD
Methylphenidate—Pancreatitis—Doxorubicin—liver cancer	0.00143	0.00155	CcSEcCtD
Methylphenidate—Weight decreased—Epirubicin—liver cancer	0.00142	0.00154	CcSEcCtD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC40A1—liver cancer	0.00142	0.0184	CbGpPWpGaD
Methylphenidate—Angina pectoris—Doxorubicin—liver cancer	0.00142	0.00154	CcSEcCtD
Methylphenidate—Pneumonia—Epirubicin—liver cancer	0.00141	0.00153	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—DNAJB1—liver cancer	0.00141	0.0182	CbGpPWpGaD
Methylphenidate—Infestation—Epirubicin—liver cancer	0.0014	0.00152	CcSEcCtD
Methylphenidate—Drowsiness—Epirubicin—liver cancer	0.0014	0.00152	CcSEcCtD
Methylphenidate—Infestation NOS—Epirubicin—liver cancer	0.0014	0.00152	CcSEcCtD
Methylphenidate—Bronchitis—Doxorubicin—liver cancer	0.0014	0.00152	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00139	0.00151	CcSEcCtD
Methylphenidate—Pancytopenia—Doxorubicin—liver cancer	0.00138	0.0015	CcSEcCtD
Methylphenidate—Conjunctivitis—Epirubicin—liver cancer	0.00136	0.00148	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00135	0.00147	CcSEcCtD
Methylphenidate—Sweating—Epirubicin—liver cancer	0.00135	0.00146	CcSEcCtD
Methylphenidate—Haematuria—Epirubicin—liver cancer	0.00134	0.00145	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Doxorubicin—liver cancer	0.00133	0.00144	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Epirubicin—liver cancer	0.00133	0.00144	CcSEcCtD
Methylphenidate—Weight increased—Doxorubicin—liver cancer	0.00133	0.00144	CcSEcCtD
Methylphenidate—Epistaxis—Epirubicin—liver cancer	0.00132	0.00144	CcSEcCtD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A2—liver cancer	0.00132	0.017	CbGpPWpGaD
Methylphenidate—Weight decreased—Doxorubicin—liver cancer	0.00132	0.00143	CcSEcCtD
Methylphenidate—Sinusitis—Epirubicin—liver cancer	0.00132	0.00143	CcSEcCtD
Methylphenidate—Pneumonia—Doxorubicin—liver cancer	0.00131	0.00142	CcSEcCtD
Methylphenidate—Infestation NOS—Doxorubicin—liver cancer	0.0013	0.00141	CcSEcCtD
Methylphenidate—Infestation—Doxorubicin—liver cancer	0.0013	0.00141	CcSEcCtD
Methylphenidate—Drowsiness—Doxorubicin—liver cancer	0.0013	0.00141	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00129	0.0014	CcSEcCtD
Methylphenidate—Bradycardia—Epirubicin—liver cancer	0.00128	0.00139	CcSEcCtD
Methylphenidate—Haemoglobin—Epirubicin—liver cancer	0.00127	0.00137	CcSEcCtD
Methylphenidate—Rhinitis—Epirubicin—liver cancer	0.00126	0.00137	CcSEcCtD
Methylphenidate—Conjunctivitis—Doxorubicin—liver cancer	0.00126	0.00137	CcSEcCtD
Methylphenidate—Haemorrhage—Epirubicin—liver cancer	0.00126	0.00137	CcSEcCtD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC40A1—liver cancer	0.00126	0.0163	CbGpPWpGaD
Methylphenidate—Pharyngitis—Epirubicin—liver cancer	0.00125	0.00136	CcSEcCtD
Methylphenidate—Sweating—Doxorubicin—liver cancer	0.00125	0.00135	CcSEcCtD
Methylphenidate—Urinary tract disorder—Epirubicin—liver cancer	0.00124	0.00135	CcSEcCtD
Methylphenidate—Haematuria—Doxorubicin—liver cancer	0.00124	0.00134	CcSEcCtD
Methylphenidate—Connective tissue disorder—Epirubicin—liver cancer	0.00124	0.00134	CcSEcCtD
Methylphenidate—Urethral disorder—Epirubicin—liver cancer	0.00124	0.00134	CcSEcCtD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.00123	0.0159	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CYCS—liver cancer	0.00123	0.0159	CbGpPWpGaD
Methylphenidate—Hepatobiliary disease—Doxorubicin—liver cancer	0.00123	0.00133	CcSEcCtD
Methylphenidate—Epistaxis—Doxorubicin—liver cancer	0.00123	0.00133	CcSEcCtD
Methylphenidate—Sinusitis—Doxorubicin—liver cancer	0.00122	0.00132	CcSEcCtD
Methylphenidate—Visual impairment—Epirubicin—liver cancer	0.00121	0.00132	CcSEcCtD
Methylphenidate—SLC6A4—Monoamine Transport—MAPK14—liver cancer	0.0012	0.0155	CbGpPWpGaD
Methylphenidate—Erythema multiforme—Epirubicin—liver cancer	0.00119	0.00129	CcSEcCtD
Methylphenidate—Bradycardia—Doxorubicin—liver cancer	0.00119	0.00129	CcSEcCtD
Methylphenidate—Eye disorder—Epirubicin—liver cancer	0.00118	0.00128	CcSEcCtD
Methylphenidate—Haemoglobin—Doxorubicin—liver cancer	0.00117	0.00127	CcSEcCtD
Methylphenidate—Flushing—Epirubicin—liver cancer	0.00117	0.00127	CcSEcCtD
Methylphenidate—Cardiac disorder—Epirubicin—liver cancer	0.00117	0.00127	CcSEcCtD
Methylphenidate—Rhinitis—Doxorubicin—liver cancer	0.00117	0.00127	CcSEcCtD
Methylphenidate—Haemorrhage—Doxorubicin—liver cancer	0.00117	0.00126	CcSEcCtD
Methylphenidate—Pharyngitis—Doxorubicin—liver cancer	0.00116	0.00125	CcSEcCtD
Methylphenidate—Urinary tract disorder—Doxorubicin—liver cancer	0.00115	0.00125	CcSEcCtD
Methylphenidate—Connective tissue disorder—Doxorubicin—liver cancer	0.00115	0.00124	CcSEcCtD
Methylphenidate—Angiopathy—Epirubicin—liver cancer	0.00114	0.00124	CcSEcCtD
Methylphenidate—Urethral disorder—Doxorubicin—liver cancer	0.00114	0.00124	CcSEcCtD
Methylphenidate—Immune system disorder—Epirubicin—liver cancer	0.00114	0.00123	CcSEcCtD
Methylphenidate—Mediastinal disorder—Epirubicin—liver cancer	0.00114	0.00123	CcSEcCtD
Methylphenidate—Chills—Epirubicin—liver cancer	0.00113	0.00123	CcSEcCtD
Methylphenidate—Arrhythmia—Epirubicin—liver cancer	0.00113	0.00122	CcSEcCtD
Methylphenidate—Visual impairment—Doxorubicin—liver cancer	0.00112	0.00122	CcSEcCtD
Methylphenidate—Alopecia—Epirubicin—liver cancer	0.00111	0.00121	CcSEcCtD
Methylphenidate—Mental disorder—Epirubicin—liver cancer	0.0011	0.0012	CcSEcCtD
Methylphenidate—Erythema multiforme—Doxorubicin—liver cancer	0.0011	0.0012	CcSEcCtD
Methylphenidate—Malnutrition—Epirubicin—liver cancer	0.0011	0.00119	CcSEcCtD
Methylphenidate—Erythema—Epirubicin—liver cancer	0.0011	0.00119	CcSEcCtD
Methylphenidate—Eye disorder—Doxorubicin—liver cancer	0.00109	0.00118	CcSEcCtD
Methylphenidate—Flushing—Doxorubicin—liver cancer	0.00108	0.00117	CcSEcCtD
Methylphenidate—Cardiac disorder—Doxorubicin—liver cancer	0.00108	0.00117	CcSEcCtD
Methylphenidate—Tension—Epirubicin—liver cancer	0.00108	0.00117	CcSEcCtD
Methylphenidate—Nervousness—Epirubicin—liver cancer	0.00107	0.00116	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—GSTA3—liver cancer	0.00106	0.0137	CbGpPWpGaD
Methylphenidate—Back pain—Epirubicin—liver cancer	0.00106	0.00115	CcSEcCtD
Methylphenidate—Angiopathy—Doxorubicin—liver cancer	0.00106	0.00115	CcSEcCtD
Methylphenidate—Muscle spasms—Epirubicin—liver cancer	0.00105	0.00114	CcSEcCtD
Methylphenidate—Immune system disorder—Doxorubicin—liver cancer	0.00105	0.00114	CcSEcCtD
Methylphenidate—Mediastinal disorder—Doxorubicin—liver cancer	0.00105	0.00114	CcSEcCtD
Methylphenidate—Chills—Doxorubicin—liver cancer	0.00105	0.00113	CcSEcCtD
Methylphenidate—Arrhythmia—Doxorubicin—liver cancer	0.00104	0.00113	CcSEcCtD
Methylphenidate—SLC6A2—Monoamine Transport—MAPK14—liver cancer	0.00104	0.0134	CbGpPWpGaD
Methylphenidate—Vision blurred—Epirubicin—liver cancer	0.00103	0.00112	CcSEcCtD
Methylphenidate—CYP2D6—Xenobiotics—CYP2E1—liver cancer	0.00103	0.0133	CbGpPWpGaD
Methylphenidate—Alopecia—Doxorubicin—liver cancer	0.00103	0.00112	CcSEcCtD
Methylphenidate—Mental disorder—Doxorubicin—liver cancer	0.00102	0.00111	CcSEcCtD
Methylphenidate—Ill-defined disorder—Epirubicin—liver cancer	0.00102	0.0011	CcSEcCtD
Methylphenidate—Erythema—Doxorubicin—liver cancer	0.00102	0.0011	CcSEcCtD
Methylphenidate—Malnutrition—Doxorubicin—liver cancer	0.00102	0.0011	CcSEcCtD
Methylphenidate—Anaemia—Epirubicin—liver cancer	0.00101	0.0011	CcSEcCtD
Methylphenidate—Agitation—Epirubicin—liver cancer	0.00101	0.00109	CcSEcCtD
Methylphenidate—Tension—Doxorubicin—liver cancer	0.000996	0.00108	CcSEcCtD
Methylphenidate—CYP2D6—Tamoxifen metabolism—CYP2E1—liver cancer	0.000992	0.0128	CbGpPWpGaD
Methylphenidate—Malaise—Epirubicin—liver cancer	0.000989	0.00107	CcSEcCtD
Methylphenidate—Nervousness—Doxorubicin—liver cancer	0.000986	0.00107	CcSEcCtD
Methylphenidate—Vertigo—Epirubicin—liver cancer	0.000986	0.00107	CcSEcCtD
Methylphenidate—Syncope—Epirubicin—liver cancer	0.000984	0.00107	CcSEcCtD
Methylphenidate—Leukopenia—Epirubicin—liver cancer	0.000982	0.00106	CcSEcCtD
Methylphenidate—Back pain—Doxorubicin—liver cancer	0.000982	0.00106	CcSEcCtD
Methylphenidate—Muscle spasms—Doxorubicin—liver cancer	0.000976	0.00106	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—GSTA4—liver cancer	0.000972	0.0125	CbGpPWpGaD
Methylphenidate—Palpitations—Epirubicin—liver cancer	0.000969	0.00105	CcSEcCtD
Methylphenidate—Loss of consciousness—Epirubicin—liver cancer	0.000964	0.00105	CcSEcCtD
Methylphenidate—Cough—Epirubicin—liver cancer	0.000957	0.00104	CcSEcCtD
Methylphenidate—Vision blurred—Doxorubicin—liver cancer	0.000957	0.00104	CcSEcCtD
Methylphenidate—Convulsion—Epirubicin—liver cancer	0.00095	0.00103	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—GSTA2—liver cancer	0.000948	0.0122	CbGpPWpGaD
Methylphenidate—Hypertension—Epirubicin—liver cancer	0.000947	0.00103	CcSEcCtD
Methylphenidate—Ill-defined disorder—Doxorubicin—liver cancer	0.000942	0.00102	CcSEcCtD
Methylphenidate—Anaemia—Doxorubicin—liver cancer	0.000938	0.00102	CcSEcCtD
Methylphenidate—Myalgia—Epirubicin—liver cancer	0.000934	0.00101	CcSEcCtD
Methylphenidate—Chest pain—Epirubicin—liver cancer	0.000934	0.00101	CcSEcCtD
Methylphenidate—Arthralgia—Epirubicin—liver cancer	0.000934	0.00101	CcSEcCtD
Methylphenidate—Agitation—Doxorubicin—liver cancer	0.000933	0.00101	CcSEcCtD
Methylphenidate—Anxiety—Epirubicin—liver cancer	0.000931	0.00101	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000928	0.00101	CcSEcCtD
Methylphenidate—Discomfort—Epirubicin—liver cancer	0.000923	0.001	CcSEcCtD
Methylphenidate—SLC6A3—Monoamine Transport—MAPK14—liver cancer	0.000917	0.0118	CbGpPWpGaD
Methylphenidate—Malaise—Doxorubicin—liver cancer	0.000915	0.000992	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—GSTA1—liver cancer	0.000914	0.0118	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTA3—liver cancer	0.000914	0.0118	CbGpPWpGaD
Methylphenidate—Dry mouth—Epirubicin—liver cancer	0.000913	0.00099	CcSEcCtD
Methylphenidate—Vertigo—Doxorubicin—liver cancer	0.000912	0.000989	CcSEcCtD
Methylphenidate—Syncope—Doxorubicin—liver cancer	0.00091	0.000987	CcSEcCtD
Methylphenidate—Leukopenia—Doxorubicin—liver cancer	0.000909	0.000985	CcSEcCtD
Methylphenidate—Confusional state—Epirubicin—liver cancer	0.000903	0.000979	CcSEcCtD
Methylphenidate—Palpitations—Doxorubicin—liver cancer	0.000897	0.000972	CcSEcCtD
Methylphenidate—Oedema—Epirubicin—liver cancer	0.000895	0.000971	CcSEcCtD
Methylphenidate—Anaphylactic shock—Epirubicin—liver cancer	0.000895	0.000971	CcSEcCtD
Methylphenidate—Loss of consciousness—Doxorubicin—liver cancer	0.000892	0.000967	CcSEcCtD
Methylphenidate—Infection—Epirubicin—liver cancer	0.000889	0.000964	CcSEcCtD
Methylphenidate—Cough—Doxorubicin—liver cancer	0.000886	0.00096	CcSEcCtD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.000886	0.0114	CbGpPWpGaD
Methylphenidate—Shock—Epirubicin—liver cancer	0.000881	0.000955	CcSEcCtD
Methylphenidate—Convulsion—Doxorubicin—liver cancer	0.000879	0.000953	CcSEcCtD
Methylphenidate—Nervous system disorder—Epirubicin—liver cancer	0.000878	0.000952	CcSEcCtD
Methylphenidate—Thrombocytopenia—Epirubicin—liver cancer	0.000877	0.00095	CcSEcCtD
Methylphenidate—Hypertension—Doxorubicin—liver cancer	0.000876	0.00095	CcSEcCtD
Methylphenidate—Tachycardia—Epirubicin—liver cancer	0.000874	0.000947	CcSEcCtD
Methylphenidate—Skin disorder—Epirubicin—liver cancer	0.00087	0.000943	CcSEcCtD
Methylphenidate—Hyperhidrosis—Epirubicin—liver cancer	0.000866	0.000938	CcSEcCtD
Methylphenidate—Myalgia—Doxorubicin—liver cancer	0.000864	0.000937	CcSEcCtD
Methylphenidate—Chest pain—Doxorubicin—liver cancer	0.000864	0.000937	CcSEcCtD
Methylphenidate—Arthralgia—Doxorubicin—liver cancer	0.000864	0.000937	CcSEcCtD
Methylphenidate—Anxiety—Doxorubicin—liver cancer	0.000861	0.000934	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000858	0.00093	CcSEcCtD
Methylphenidate—Discomfort—Doxorubicin—liver cancer	0.000854	0.000926	CcSEcCtD
Methylphenidate—Anorexia—Epirubicin—liver cancer	0.000853	0.000925	CcSEcCtD
Methylphenidate—Dry mouth—Doxorubicin—liver cancer	0.000845	0.000916	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—GSTA4—liver cancer	0.000836	0.0108	CbGpPWpGaD
Methylphenidate—Confusional state—Doxorubicin—liver cancer	0.000835	0.000906	CcSEcCtD
Methylphenidate—Oedema—Doxorubicin—liver cancer	0.000828	0.000898	CcSEcCtD
Methylphenidate—Anaphylactic shock—Doxorubicin—liver cancer	0.000828	0.000898	CcSEcCtD
Methylphenidate—Infection—Doxorubicin—liver cancer	0.000823	0.000892	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000816	0.000884	CcSEcCtD
Methylphenidate—Shock—Doxorubicin—liver cancer	0.000815	0.000884	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—GSTA2—liver cancer	0.000815	0.0105	CbGpPWpGaD
Methylphenidate—Nervous system disorder—Doxorubicin—liver cancer	0.000812	0.000881	CcSEcCtD
Methylphenidate—Thrombocytopenia—Doxorubicin—liver cancer	0.000811	0.000879	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—GSTA3—liver cancer	0.00081	0.0104	CbGpPWpGaD
Methylphenidate—Insomnia—Epirubicin—liver cancer	0.00081	0.000878	CcSEcCtD
Methylphenidate—Tachycardia—Doxorubicin—liver cancer	0.000809	0.000876	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—NFE2L2—liver cancer	0.000806	0.0104	CbGpPWpGaD
Methylphenidate—Skin disorder—Doxorubicin—liver cancer	0.000805	0.000872	CcSEcCtD
Methylphenidate—Paraesthesia—Epirubicin—liver cancer	0.000804	0.000872	CcSEcCtD
Methylphenidate—Hyperhidrosis—Doxorubicin—liver cancer	0.000801	0.000868	CcSEcCtD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—MAPK14—liver cancer	0.000799	0.0103	CbGpPWpGaD
Methylphenidate—Dyspnoea—Epirubicin—liver cancer	0.000798	0.000865	CcSEcCtD
Methylphenidate—Somnolence—Epirubicin—liver cancer	0.000796	0.000863	CcSEcCtD
Methylphenidate—Anorexia—Doxorubicin—liver cancer	0.00079	0.000856	CcSEcCtD
Methylphenidate—Dyspepsia—Epirubicin—liver cancer	0.000788	0.000854	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—GSTA1—liver cancer	0.000786	0.0101	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000786	0.0101	CbGpPWpGaD
Methylphenidate—Decreased appetite—Epirubicin—liver cancer	0.000778	0.000844	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Epirubicin—liver cancer	0.000773	0.000838	CcSEcCtD
Methylphenidate—Fatigue—Epirubicin—liver cancer	0.000772	0.000837	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—TGFA—liver cancer	0.000769	0.00991	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GPX3—liver cancer	0.000769	0.00991	CbGpPWpGaD
Methylphenidate—Constipation—Epirubicin—liver cancer	0.000766	0.00083	CcSEcCtD
Methylphenidate—Pain—Epirubicin—liver cancer	0.000766	0.00083	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—SERPINA1—liver cancer	0.000757	0.00977	CbGpPWpGaD
Methylphenidate—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000755	0.000818	CcSEcCtD
Methylphenidate—Insomnia—Doxorubicin—liver cancer	0.000749	0.000812	CcSEcCtD
Methylphenidate—Paraesthesia—Doxorubicin—liver cancer	0.000744	0.000806	CcSEcCtD
Methylphenidate—CYP2D6—Xenobiotics—CYP1A1—liver cancer	0.000741	0.00956	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTA4—liver cancer	0.000741	0.00955	CbGpPWpGaD
Methylphenidate—Dyspnoea—Doxorubicin—liver cancer	0.000739	0.000801	CcSEcCtD
Methylphenidate—Feeling abnormal—Epirubicin—liver cancer	0.000738	0.0008	CcSEcCtD
Methylphenidate—Somnolence—Doxorubicin—liver cancer	0.000736	0.000798	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Epirubicin—liver cancer	0.000732	0.000794	CcSEcCtD
Methylphenidate—Dyspepsia—Doxorubicin—liver cancer	0.000729	0.000791	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—GSTA2—liver cancer	0.000722	0.00931	CbGpPWpGaD
Methylphenidate—Decreased appetite—Doxorubicin—liver cancer	0.00072	0.000781	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000715	0.000775	CcSEcCtD
Methylphenidate—Fatigue—Doxorubicin—liver cancer	0.000714	0.000774	CcSEcCtD
Methylphenidate—CYP2D6—Tamoxifen metabolism—CYP1A1—liver cancer	0.000712	0.00919	CbGpPWpGaD
Methylphenidate—Urticaria—Epirubicin—liver cancer	0.000711	0.000771	CcSEcCtD
Methylphenidate—Pain—Doxorubicin—liver cancer	0.000708	0.000768	CcSEcCtD
Methylphenidate—Constipation—Doxorubicin—liver cancer	0.000708	0.000768	CcSEcCtD
Methylphenidate—Abdominal pain—Epirubicin—liver cancer	0.000708	0.000767	CcSEcCtD
Methylphenidate—Body temperature increased—Epirubicin—liver cancer	0.000708	0.000767	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—GSTA1—liver cancer	0.000696	0.00898	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—NFE2L2—liver cancer	0.000693	0.00894	CbGpPWpGaD
Methylphenidate—Feeling abnormal—Doxorubicin—liver cancer	0.000683	0.00074	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.000678	0.00874	CbGpPWpGaD
Methylphenidate—Gastrointestinal pain—Doxorubicin—liver cancer	0.000677	0.000734	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000673	0.00868	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000673	0.00868	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GLUL—liver cancer	0.000664	0.00857	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—TGFA—liver cancer	0.000661	0.00853	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GPX3—liver cancer	0.000661	0.00853	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Epirubicin—liver cancer	0.00066	0.000715	CcSEcCtD
Methylphenidate—Urticaria—Doxorubicin—liver cancer	0.000658	0.000713	CcSEcCtD
Methylphenidate—Body temperature increased—Doxorubicin—liver cancer	0.000655	0.00071	CcSEcCtD
Methylphenidate—Abdominal pain—Doxorubicin—liver cancer	0.000655	0.00071	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—SERPINA1—liver cancer	0.000651	0.0084	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.000646	0.00834	CbGpPWpGaD
Methylphenidate—Asthenia—Epirubicin—liver cancer	0.000642	0.000696	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—AHR—liver cancer	0.00064	0.00826	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000637	0.00822	CbGpPWpGaD
Methylphenidate—Pruritus—Epirubicin—liver cancer	0.000633	0.000687	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—NFE2L2—liver cancer	0.000614	0.00792	CbGpPWpGaD
Methylphenidate—Diarrhoea—Epirubicin—liver cancer	0.000613	0.000664	CcSEcCtD
Methylphenidate—Hypersensitivity—Doxorubicin—liver cancer	0.00061	0.000662	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.0006	0.00774	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000596	0.00769	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000596	0.00769	CbGpPWpGaD
Methylphenidate—Asthenia—Doxorubicin—liver cancer	0.000594	0.000644	CcSEcCtD
Methylphenidate—Dizziness—Epirubicin—liver cancer	0.000592	0.000642	CcSEcCtD
Methylphenidate—Pruritus—Doxorubicin—liver cancer	0.000586	0.000635	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—TGFA—liver cancer	0.000586	0.00755	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GPX3—liver cancer	0.000586	0.00755	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—UGDH—liver cancer	0.000579	0.00747	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SERPINA1—liver cancer	0.000577	0.00744	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.000573	0.00739	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—TNF—liver cancer	0.000572	0.00738	CbGpPWpGaD
Methylphenidate—Vomiting—Epirubicin—liver cancer	0.000569	0.000617	CcSEcCtD
Methylphenidate—Diarrhoea—Doxorubicin—liver cancer	0.000567	0.000614	CcSEcCtD
Methylphenidate—Rash—Epirubicin—liver cancer	0.000565	0.000612	CcSEcCtD
Methylphenidate—Dermatitis—Epirubicin—liver cancer	0.000564	0.000611	CcSEcCtD
Methylphenidate—Headache—Epirubicin—liver cancer	0.000561	0.000608	CcSEcCtD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—CYP1A1—liver cancer	0.00055	0.0071	CbGpPWpGaD
Methylphenidate—Dizziness—Doxorubicin—liver cancer	0.000548	0.000594	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—GGT1—liver cancer	0.000541	0.00698	CbGpPWpGaD
Methylphenidate—Nausea—Epirubicin—liver cancer	0.000532	0.000577	CcSEcCtD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—STAT3—liver cancer	0.00053	0.00684	CbGpPWpGaD
Methylphenidate—Vomiting—Doxorubicin—liver cancer	0.000527	0.000571	CcSEcCtD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP3—liver cancer	0.000522	0.00674	CbGpPWpGaD
Methylphenidate—Rash—Doxorubicin—liver cancer	0.000522	0.000566	CcSEcCtD
Methylphenidate—Dermatitis—Doxorubicin—liver cancer	0.000522	0.000566	CcSEcCtD
Methylphenidate—Headache—Doxorubicin—liver cancer	0.000519	0.000563	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—GLUL—liver cancer	0.000509	0.00656	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—TNF—liver cancer	0.000492	0.00635	CbGpPWpGaD
Methylphenidate—Nausea—Doxorubicin—liver cancer	0.000492	0.000533	CcSEcCtD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—TGFB1—liver cancer	0.000492	0.00634	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTP1—liver cancer	0.000486	0.00627	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—HMOX1—liver cancer	0.000479	0.00618	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GGT1—liver cancer	0.000465	0.006	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTM1—liver cancer	0.000446	0.00576	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—HGF—liver cancer	0.000446	0.00576	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—TNF—liver cancer	0.000436	0.00562	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000428	0.00552	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000423	0.00545	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTP1—liver cancer	0.000418	0.00539	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GGT1—liver cancer	0.000412	0.00531	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—HMOX1—liver cancer	0.000412	0.00531	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTM1—liver cancer	0.000384	0.00495	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—HGF—liver cancer	0.000384	0.00495	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTP1—liver cancer	0.00037	0.00477	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—HMOX1—liver cancer	0.000365	0.00471	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000347	0.00448	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000344	0.00444	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTM1—liver cancer	0.00034	0.00439	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—HGF—liver cancer	0.00034	0.00439	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—NR1H4—liver cancer	0.000338	0.00437	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA3—liver cancer	0.000333	0.00429	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000328	0.00424	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTA3—liver cancer	0.000328	0.00423	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000315	0.00406	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000315	0.00406	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000308	0.00397	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000305	0.00393	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA4—liver cancer	0.000304	0.00393	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000304	0.00392	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTA4—liver cancer	0.0003	0.00387	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARA—liver cancer	0.0003	0.00387	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000298	0.00384	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA2—liver cancer	0.000297	0.00383	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000291	0.00375	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA1—liver cancer	0.000286	0.00369	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—NAT2—liver cancer	0.000283	0.00365	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—NAT2—liver cancer	0.000279	0.0036	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000279	0.0036	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000279	0.0036	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000264	0.0034	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000249	0.00322	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARG—liver cancer	0.000248	0.0032	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GPX3—liver cancer	0.000237	0.00306	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—HPGDS—liver cancer	0.000226	0.00292	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—SERPINE1—liver cancer	0.000223	0.00288	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CASP3—liver cancer	0.000222	0.00286	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—JUN—liver cancer	0.000215	0.00278	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—liver cancer	0.000214	0.00276	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—liver cancer	0.000188	0.00243	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—BRAF—liver cancer	0.000185	0.00238	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2E1—liver cancer	0.000184	0.00238	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—TGFB1—liver cancer	0.000182	0.00235	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP2E1—liver cancer	0.000182	0.00235	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—JUN—liver cancer	0.000176	0.00227	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GGT1—liver cancer	0.000169	0.00218	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—MAPK8—liver cancer	0.000166	0.00214	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TNF—liver cancer	0.000161	0.00208	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—TGFB1—liver cancer	0.000156	0.00202	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—ALB—liver cancer	0.000156	0.00201	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—RAF1—liver cancer	0.000154	0.00199	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTP1—liver cancer	0.000152	0.00196	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—CYCS—liver cancer	0.000152	0.00196	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTP1—liver cancer	0.00015	0.00193	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—BRAF—liver cancer	0.000141	0.00182	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTM1—liver cancer	0.00014	0.0018	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—TGFB1—liver cancer	0.000139	0.00179	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—ALB—liver cancer	0.000138	0.00178	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTM1—liver cancer	0.000138	0.00178	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CYCS—liver cancer	0.000134	0.00173	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP1A1—liver cancer	0.000132	0.00171	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000132	0.0017	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP1A1—liver cancer	0.000131	0.00169	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL6—liver cancer	0.00013	0.00168	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—RAF1—liver cancer	0.000118	0.00152	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000117	0.00151	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—liver cancer	0.000116	0.0015	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—PPARA—liver cancer	0.000107	0.00138	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—IL6—liver cancer	0.000106	0.00137	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UGDH—liver cancer	9.91e-05	0.00128	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—PPARA—liver cancer	9.44e-05	0.00122	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—EPT1—liver cancer	9.31e-05	0.0012	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TAT—liver cancer	8.83e-05	0.00114	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—HRAS—liver cancer	8.48e-05	0.00109	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ALB—liver cancer	7.92e-05	0.00102	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—RAF1—liver cancer	7.17e-05	0.000924	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ALB—liver cancer	7.02e-05	0.000905	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—HRAS—liver cancer	6.5e-05	0.000839	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—RAF1—liver cancer	6.35e-05	0.000819	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GLUL—liver cancer	6e-05	0.000774	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CPT1B—liver cancer	6e-05	0.000774	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NR1H4—liver cancer	5.79e-05	0.000747	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA3—liver cancer	5.69e-05	0.000734	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA4—liver cancer	5.2e-05	0.000671	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA2—liver cancer	5.07e-05	0.000654	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA1—liver cancer	4.89e-05	0.000631	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NAT2—liver cancer	4.84e-05	0.000624	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALDOB—liver cancer	4.64e-05	0.000598	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CRABP1—liver cancer	4.43e-05	0.000571	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HPGDS—liver cancer	3.87e-05	0.000499	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PSMA4—liver cancer	3.45e-05	0.000445	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PSMD10—liver cancer	3.45e-05	0.000445	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GOT2—liver cancer	3.35e-05	0.000433	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2E1—liver cancer	3.15e-05	0.000407	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYCS—liver cancer	2.95e-05	0.000381	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GOT1—liver cancer	2.89e-05	0.000373	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GGT1—liver cancer	2.89e-05	0.000373	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTP1—liver cancer	2.6e-05	0.000335	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HMOX1—liver cancer	2.56e-05	0.000331	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTM1—liver cancer	2.39e-05	0.000308	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP1A1—liver cancer	2.27e-05	0.000292	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MTHFR—liver cancer	2.11e-05	0.000272	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARA—liver cancer	2.07e-05	0.000267	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CG—liver cancer	1.77e-05	0.000229	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARG—liver cancer	1.71e-05	0.000221	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CD—liver cancer	1.56e-05	0.000201	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALB—liver cancer	1.54e-05	0.000199	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CB—liver cancer	1.36e-05	0.000175	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CA—liver cancer	8.29e-06	0.000107	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKT1—liver cancer	6.77e-06	8.73e-05	CbGpPWpGaD
